“The present situation has exposed some structural weaknesses while in the EU’s medicines source chain and also a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She suggested that supply chain concerns be dealt with within an EU pharmaceutical method anticipated to generally